Esophageal cancer pipeline review, q3 2011

456 views

Published on

This report provides information on the therapeutic development for Esophageal Cancer, complete with latest updates, and special features on late-stage and discontinued projects.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
456
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Esophageal cancer pipeline review, q3 2011

  1. 1. Esophageal Cancer - Pipeline Review, Q3 2011Published:July 2011No.Of Pages:133Price:US $ 500Report SummaryGlobal Markets Direct’s, Esophageal Cancer - Pipeline Review, Q3 2011, providesan overview of the Esophageal Cancer therapeutic pipeline. This report providesinformation on the therapeutic development for Esophageal Cancer, complete withlatest updates, and special features on late-stage and discontinued projects. It alsoreviews key players involved in the therapeutic development for EsophagealCancer. Esophageal Cancer - Pipeline Review, Q3 2011 is built using data andinformation sourced from Global Markets Direct’s proprietary databases,Company/University websites, SEC filings, investor presentations and featuredpress releases from company/university sites and industry-specific third partysources, put together by Global Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope* A snapshot of the global therapeutic scenario for Esophageal Cancer.* A review of the Esophageal Cancer products under development by companiesand universities/research institutes based on information derived from companyand industry-specific sources.* Coverage of products based on various stages of development ranging fromdiscovery till registration stages.* A feature on pipeline projects on the basis of monotherapy and combinedtherapeutics.* Coverage of the Esophageal Cancer pipeline on the basis of therapeutic class,route of administration and molecule type.* Profiles of late-stage pipeline products featuring sections on product description,mechanism of action and research & development progress.* Key discontinued pipeline projects.* Latest news and deals relating to the products.Browse All Pharmaceuticals Market Research
  2. 2. Reasons to buy* Identify and understand important and diverse types of therapeutics underdevelopment for Esophageal Cancer.* Identify emerging players with potentially strong product portfolio and designeffective counter-strategies to gain competitive advantage.* Plan mergers and acquisitions effectively by identifying players with the mostpromising pipeline.* Devise corrective measures for pipeline projects by understanding EsophagealCancer pipeline depth and focus of Esophageal Cancer therapeutics.* Develop and design in-licensing and out-licensing strategies by identifyingprospective partners with the most attractive projects to enhance and expandbusiness potential and scope.* Modify the therapeutic portfolio by identifying discontinued projects andunderstanding the factors that drove them from pipeline.Table of ContentsTable of Contents 2List of Tables 7List of Figures 9Introduction 10Global Markets Direct Report Coverage 10Esophageal Cancer Overview 11Therapeutics Development 12An Overview of Pipeline Products for Esophageal Cancer 12Esophageal Cancer Therapeutics under Development by Companies 14Esophageal Cancer Therapeutics under Investigation by Universities/Institutes 16Late Stage Products 27Comparative Analysis 27Mid Clinical Stage Products 28Comparative Analysis 28Early Clinical Stage Products 29Comparative Analysis 29Discovery and Pre-Clinical Stage Products 30Comparative Analysis 30Esophageal Cancer Therapeutics - Products under Development by Companies 31Esophageal Cancer Therapeutics - Products under Investigation byUniversities/Institutes 33Companies Involved in Esophageal Cancer Therapeutics Development 53Bristol-Myers Squibb Company 53F. Hoffmann-La Roche Ltd. 53Shionogi & Co., Ltd. 54
  3. 3. Amgen Inc. 54Sanofi-Aventis 55Eli Lilly and Company 55GlaxoSmithKline plc 56GenVec, Inc. 56Micromet, Inc. 57Aphios Corporation 57Cell Therapeutics, Inc. 58MannKind Corporation 58Celldex Therapeutics, Inc. 59BTG International Ltd 59Sareum Holdings plc 60Supratek Pharma Inc. 60GANYMED Pharmaceuticals AG 61Ascenta Therapeutics, Inc. 61Merrimack Pharmaceuticals, Inc. 62PharmaMar, S.A. 62Krankenhaus-GmbH 63ImmunoFrontier, Inc. 63Mebiopharm Co., Ltd. 64Eurofarma 64Biotech Pharmaceuticals Co., Ltd. 65Esophageal Cancer - Therapeutics Assessment 66Assessment by Monotherapy Products 66Assessment by Combination Products 67Assessment by Route of Administration 68Assessment by Molecule Type 71Late Stage Drug Profiles 74FOLFOX4 - Drug Profile 74Product Description 74Mechanism of Action 74R&D Progress 74Docetaxel + Active Symptom Control - Drug Profile 76Product Description 76Mechanism of Action 76R&D Progress 76Tykerb + Capecitabine + Oxaliplatin - Drug Profile 77Product Description 77Mechanism of Action 77R&D Progress 77Cisplatin + Capecitabine + Radiation Therapy - Drug Profile 79Product Description 79Mechanism of Action 79R&D Progress 79Paclitaxel + Cisplatin + Cetuximab + Radiation Therapy - Drug Profile 81Product Description 81Mechanism of Action 81
  4. 4. R&D Progress 81Cetuximab + Cisplatin + Docetaxel + Radiation Therapy - Drug Profile 83Product Description 83Mechanism of Action 83R&D Progress 84Fluorouracil + Cisplatin + Radiation Therapy - Drug Profile 85Product Description 85Mechanism of Action 85R&D Progress 85Epirubicin + Oxaliplatin + Capecitabine + Panitumumab - Drug Profile 87Product Description 87Mechanism of Action 87R&D Progress 87Herceptin + Xeloda - Drug Profile 88Product Description 88Mechanism of Action 88R&D Progress 88cisplatin + fluorouracil - Drug Profile 89Product Description 89Mechanism of Action 89R&D Progress 89cisplatin + fluorouracil - Drug Profile 91Product Description 91Mechanism of Action 91R&D Progress 91CapeOx + Lapatinib - Drug Profile 93Product Description 93Mechanism of Action 93R&D Progress 93Cisplatin + Capecitabine + Cetuximab + Radiation Therapy - Drug Profile 95Product Description 95Mechanism of Action 95R&D Progress 95Fluorouracil + Cisplatin + Epirubicin Hydrochloride + Radiation Therapy - DrugProfile 96Product Description 96Mechanism of Action 96R&D Progress 96Cisplatin + Epirubicin + Fluorouracil - Drug Profile 97Product Description 97Mechanism of Action 97R&D Progress 97Esomeprazole + Aspirin - Drug Profile 99Product Description 99Mechanism of Action 99R&D Progress 99Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 100
  5. 5. Product Description 100Mechanism of Action 100R&D Progress 100Lobaplatin + 5-Fluorouracil + Leucovorin - Drug Profile 101Product Description 101Mechanism of Action 101R&D Progress 101Paclitaxel + Cisplatin + Tarceva + Radiotherapy - Drug Profile 103Product Description 103Mechanism of Action 103R&D Progress 104Paclitaxel + Cisplatin + Radiotherapy - Drug Profile 105Product Description 105Mechanism of Action 105R&D Progress 105Iressa - Drug Profile 107Product Description 107Mechanism of Action 107R&D Progress 107Fluorouracil + Cisplatin - Drug Profile 108Product Description 108Mechanism of Action 108R&D Progress 108Docetaxel + Nedaplatin - Drug Profile 109Product Description 109Mechanism of Action 109R&D Progress 109Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 111Product Description 111Mechanism of Action 111R&D Progress 111Irinotecan hydrochloride trihydrate + Cisplatin - Drug Profile 112Product Description 112Mechanism of Action 112R&D Progress 112Cisplatin + 5-Fluorouracil + Radical radiotherapy - Drug Profile 113Product Description 113Mechanism of Action 113R&D Progress 113Cisplatinum + Fluorouracil - Drug Profile 114Product Description 114Mechanism of Action 114R&D Progress 114FOLFOX regimen + cisplatin + fluorouracil + leucovorin calcium + oxaliplatin - DrugProfile 115Product Description 115Mechanism of Action 115
  6. 6. R&D Progress 116Cisplatin + Fluorouracil - Drug Profile 117Product Description 117Mechanism of Action 117R&D Progress 117Esomeprazole - Drug Profile 118Product Description 118Mechanism of Action 118R&D Progress 118Navelbine + Cisplatin + Radiotherapy - Drug Profile 119Product Description 119Mechanism of Action 119R&D Progress 119Trastuzumab + Carboplatin + Paclitaxel + Radiation Therapy - Drug Profile 120Product Description 120Mechanism of Action 120R&D Progress 121Nimotuzumab + Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 122Product Description 122Mechanism of Action 122R&D Progress 122FOLFOX 4 + Radiochemotherapy - Drug Profile 124Product Description 124Mechanism of Action 124R&D Progress 124Esophageal Cancer Therapeutics - Discontinued Products 125Esophageal Cancer - Featured News 126Feb 23, 2011: CTI Announces Publication Of Phase II Study Results Of OPAXIO InAmerican Journal Of Clinical Oncology 126Jul 07, 2010: OPAXIO Phase II Study Results Confirm High Rate Of CompleteResponse With Low Rate Of Side Effects In Patients With Advanced EsophagealCancer 126Apr 22, 2010: Genentech Submits Supplemental Application To FDA For HerceptinIn Advanced HER2-Positive Stomach Cancer 127Feb 04, 2010: Proteo, Inc./Proteo Biotech AG: Orphan Drug Designation For ElafinIn The Treatment Of Oesophagus Carcinoma 128Nov 16, 2009: Proteo, Inc./Proteo Biotech AG: European Medicines Agency EMEARecommends Orphan Drug Status For Elafin In The Treatment Of EsophagusCarcinoma 128Sep 14, 2009: Celldex Therapeutics Announces Dosing Of First Patient In Phase I/IIClinical Trial Of CDX-1401 129Jun 03, 2009: Paclitaxel Poliglumex (OPAXIO) Added To Cisplatin And RadiationProduces 45% Pathologic Complete Remissions In Patients With Esophageal Cancer129Feb 02, 2009: Shionogi announces it has entered into a licensing agreement onPeptide vaccines for cancer treatment with OncoTherapy Science, Inc. 130Sep 24, 2008: OPAXIO Phase II Trial In Esophageal Cancer To Be Presented In
  7. 7. Proffered Session At The International Society Of Gastrointestinal Oncology AnnualMeeting 130Jan 24, 2008: Protherics Starts OncoGel Phase IIb Study In Oesophageal Cancer131Appendix 132Methodology 132Coverage 132Secondary Research 132Primary Research 132Expert Panel Validation 133Contact Us 133Disclaimer 133List of TablesNumber of Products Under Development for Esophageal Cancer, Q3 2011 12Products under Development for Esophageal Cancer – Comparative Analysis, Q32011 13Number of Products under Development by Companies, Q3 2011 15Number of Products under Investigation by Universities/Institutes, Q3 2011 17Number of Products under Investigation by Universities/Institutes, Q3 2011 18Number of Products under Investigation by Universities/Institutes, Q3 2011 19Number of Products under Investigation by Universities/Institutes, Q3 2011 20Number of Products under Investigation by Universities/Institutes, Q3 2011 21Number of Products under Investigation by Universities/Institutes, Q3 2011 22Number of Products under Investigation by Universities/Institutes, Q3 2011 23Number of Products under Investigation by Universities/Institutes, Q3 2011 24Number of Products under Investigation by Universities/Institutes, Q3 2011 25Number of Products under Investigation by Universities/Institutes, Q3 2011 26Comparative Analysis by Late Stage Development, Q3 2011 27Comparative Analysis by Mid Clinical Stage Development, Q3 2011 28Comparative Analysis by Early Clinical Stage Development, Q3 2011 29Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q3 201130Products under Development by Companies, Q3 2011 31Products under Development by Companies, Q3 2011 32Products under Investigation by Universities/Institutes, Q3 2011 33Products under Investigation by Universities/Institutes, Q3 2011 34Products under Investigation by Universities/Institutes, Q3 2011 35Products under Investigation by Universities/Institutes, Q3 2011 36Products under Investigation by Universities/Institutes, Q3 2011 37Products under Investigation by Universities/Institutes, Q3 2011 38Products under Investigation by Universities/Institutes, Q3 2011 39Products under Investigation by Universities/Institutes, Q3 2011 40Products under Investigation by Universities/Institutes, Q3 2011 41Products under Investigation by Universities/Institutes, Q3 2011 42
  8. 8. Products under Investigation by Universities/Institutes, Q3 2011 43Products under Investigation by Universities/Institutes, Q3 2011 44Products under Investigation by Universities/Institutes, Q3 2011 45Products under Investigation by Universities/Institutes, Q3 2011 46Products under Investigation by Universities/Institutes, Q3 2011 47Products under Investigation by Universities/Institutes, Q3 2011 48Products under Investigation by Universities/Institutes, Q3 2011 49Products under Investigation by Universities/Institutes, Q3 2011 50Products under Investigation by Universities/Institutes, Q3 2011 51Products under Investigation by Universities/Institutes, Q3 2011 52Bristol-Myers Squibb Company, 2011 53F. Hoffmann-La Roche Ltd., 2011 53Shionogi & Co., Ltd., 2011 54Amgen Inc., 2011 54Sanofi-Aventis, 2011 55Eli Lilly and Company, 2011 55GlaxoSmithKline plc, 2011 56GenVec, Inc., 2011 56Micromet, Inc., 2011 57Aphios Corporation, 2011 57Cell Therapeutics, Inc., 2011 58MannKind Corporation, 2011 58Celldex Therapeutics, Inc., 2011 59BTG International Ltd, 2011 59Sareum Holdings plc, 2011 60Supratek Pharma Inc., 2011 60GANYMED Pharmaceuticals AG, 2011 61Ascenta Therapeutics, Inc., 2011 61Merrimack Pharmaceuticals, Inc., 2011 62PharmaMar, S.A., 2011 62Krankenhaus-GmbH, 2011 63ImmunoFrontier, Inc., 2011 63Mebiopharm Co., Ltd., 2011 64Eurofarma, 2011 64Biotech Pharmaceuticals Co., Ltd., 2011 65Assessment by Monotherapy Products, Q3 2011 66Assessment by Combination Products 67Assessment by Stage and Route of Administration, Q3 2011 70Assessment by Molecule Type, Q3 2011 73Discontinued Products 125
  9. 9. List of FiguresNumber of Products under Development for Esophageal Cancer, Q3 2011 12Products under Development for Esophageal Cancer – Comparative Analysis, Q32011 13Products under Development by Companies, Q3 2011 14Products under Investigation by Universities/Institutes, Q3 2011 16Late Stage Products, Q3 2011 27Mid Clinical Stage Products, Q3 2011 28Early Clinical Stage Products, Q3 2011 29Discovery and Pre-Clinical Stage Products, Q3 2011 30Assessment by Monotherapy Products, Q3 2011 66Assessment by Combination Products, Q3 2011 67Assessment by Route of Administration, Q3 2011 68Assessment by Stage and Route of Administration, Q3 2011 69Assessment by Molecule Type, Q3 2011 71Assessment by Stage and Molecule Type, Q3 2011 72About Us:ReportsnReports is an online library of over 100,000+ market research reports andin-depth market research studies & analysis of over 5000 micro markets. Weprovide 24/7 online and offline support to our customers. Get in touch with us foryour needs of market research reports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page:http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit our Market Research Blog

×